Form 4: X4 Pharmaceuticals Director William Aliski Acquires and Disposes of Shares in Recent Transaction

Director William Aliski of X4 Pharmaceuticals reports acquiring 45,000 shares and disposing of shares in a recent transaction involving restricted stock units.

Summary

• On June 10, 2024, William Aliski, a director of X4 Pharmaceuticals, engaged in a transaction involving the company's common stock.
• Aliski acquired 45,000 shares of common stock.
• Aliski also disposed of shares.
• Following the transaction, Aliski beneficially owns 96,667 shares of X4 Pharmaceuticals.
• The 45,000 shares were acquired through restricted stock units (RSUs) granted as an annual award for board service.
• These RSUs will vest fully on the earlier of June 10, 2025, or the Issuer's next annual meeting of stockholders, contingent upon continued board service.
• The RSUs will also vest fully upon a change in control of the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing a transaction. The acquisition of shares by a director is mildly positive, suggesting confidence, but it's not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future.

Future Outlook

The vesting of the RSUs is contingent upon continued board service or a change in control of the Issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates the transactions of a director at X4 Pharmaceuticals.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates